Week 1: 14–20 September 2026. No jurisdiction changed its rules on nicotine pouches this week. The regulation tracker ends the week exactly as it started it. What did happen was a new peer-reviewed paper on how people actually use pouches, and a small piece of evidence that vape-hardware money is moving into pouch manufacturing.
A quiet week is worth reporting as a quiet week. Several stories circulated in the trade press that I could not stand behind, and I have listed those at the bottom rather than passing them on.
The tracker diff
| Row | Change this week | Status |
|---|---|---|
| United States (federal) | None. FDA’s authorised list still reads 43 products, current as of 21 August 2026. | Unchanged |
| US states | None. No tobacco, nicotine or pouch bills were signed in California on 14 or 18 September. | Unchanged |
| Canada | None. The last formal step remains the Prescription Drug List amendment of 14 January 2026. | Unchanged |
| United Kingdom | No secondary legislation made. The DHSC packaging and display consultation remains open until 2 October 2026. | Unchanged |
| European Union | No Council document on tobacco excise in the window. | Unchanged |
| France, Belgium, Netherlands | None. | Unchanged |
| Nordics | None. | Unchanged |
New research: people do not use pouches the way studies assume
The one genuinely new piece of evidence this week is a qualitative study published in advance online form in Nicotine & Tobacco Research on 15 September 2026.
Tomko and colleagues ran 16 virtual focus groups with 44 adults who use oral nicotine pouches at least some days per week, and asked them how they actually use them: which lip, how long, whether they move the pouch around, whether they wet it first, whether they use more than one at a time. The finding is that the behaviour varies a great deal. In the paper’s words, “topography behaviors varied, with participants describing differing preferences for upper versus lower lip placement.”
The conclusion is the part that matters for everything else:
“ONP use patterns vary among established users. Future evaluations of abuse liability, toxicity, and health effects should consider effects across different use topographies.”
Tomko et al., A qualitative assessment of oral nicotine pouch use topography, Nicotine & Tobacco Research, DOI 10.1093/ntr/ntag211, 15 September 2026
I would not oversell this. It is 44 people, self-reporting, with no biomarkers and no exposure measurement. It does not tell you that one way of using a pouch is worse than another. What it does is undercut a quiet assumption behind a lot of the laboratory work: that a 30-minute standardised protocol represents what people do. If real use is that varied, then nicotine delivery and exposure estimates built on one protocol are narrower than they look.
Read it alongside the updated scoping review Travis and colleagues published in the same journal on 6 September, whose summary line — “ONPs are considerably less toxic than cigarettes, but their long-term health impacts remain understudied” — is still, a fortnight later, the most accurate one-sentence summary of the evidence base. That review is here.
Vape hardware money moves into pouches
Ispire Technology, a Nasdaq-listed maker of vaping hardware, filed its annual report on 15 September 2026 for the year ended 30 June. The business description now includes pouches directly: the company says it is engaged in vaping hardware “as well as the assembly of nicotine pouch products.”
Its results release the same day puts it more plainly: “We have also begun to expand beyond vaping through our joint venture with Jincheng Pharma, giving us a platform to enter the rapidly growing nicotine pouch market.”
The numbers around that ambition are not comfortable. Ispire reported full-year revenue of $96.0 million, down from $127.5 million, a net loss of $33.2 million, and $19.3 million of cash at 30 June. Fourth-quarter revenue of $26.7 million was up 33% year on year, so the trend improved late. The filings disclose no pouch revenue, no capacity, no brand name, no target market and no timeline, and Ispire holds a non-controlling interest in the joint venture.
So this is not a product launch. It is a signal, and a fairly legible one: the hardware side of the nicotine industry now sees pouch assembly as somewhere worth putting capital, at a moment when its own category is under pressure. Watch for the first named product; until there is one, there is nothing to review.
Sources: Ispire Form 10-K, 15 September 2026; FY2026 results release, furnished on Form 8-K.
Corporate: PMI raises its dividend
Philip Morris International announced on 18 September 2026 an 8.8% increase in its quarterly dividend, from $1.47 to $1.60 a share, an annualised $6.40, payable 26 October to holders of record on 2 October.
This is ZYN’s owner, so it is context rather than news about pouches — the filing contains no ZYN volumes, no guidance and no regulatory content, only the standard portfolio sentence noting that the FDA “has authorized the marketing of Swedish Match’s General snus, ZYN nicotine pouches and versions of PMI’s IQOS.” I include it because a reader tracking the category should know the cash position of the company that dominates it, not because anything about the product changed. PMI Form 8-K, 18 September 2026.
Just outside the window
Two items dated shortly before this week still have not been widely picked up, and both change what is on shelves.
On 9 September 2026 PMI’s US arm announced an expanded ZYN range: new dry pouch strengths at 1.5 mg and 8 mg alongside the existing 3 mg and 6 mg, the ZYN ULTRA moist line at 9 mg and 11 mg, and a move of the 3 mg and 6 mg dry variants to 20 pouches per can in the fourth quarter. The can-count change is the one most users will notice at the till. Company release, 9 September 2026.
On 21 August 2026 the FDA authorised 11 ZYN ULTRA products, taking the authorised total to 43. The agency’s own framing was comparative, not reassuring: the products “contain lower levels of most harmful and potentially harmful constituents (HPHCs) when compared to other oral and smokeless tobacco products.” FDA, 21 August 2026.
What I checked and did not report
Four stories ran somewhere this week that are not in the tables above, because I could not find the underlying document.
- Health Canada softening the pharmacy-only rule. Reported on 14 and 18 September. Health Canada’s own announcements page carries nothing on pouches in the window, and the Prescription Drug List notice still dates to 14 January 2026. This rests on ministerial remarks to reporters. If it becomes policy it will appear in the Canada Gazette first.
- EU minimum pouch taxes paused over Swedish objections. The informal ECOFIN did meet in Dublin on 18–19 September, but tobacco excise appears on neither the Council’s published forward look nor the presidency agenda.
- Reynolds joining a challenge to FDA review timelines in the Northern District of Texas. Dated 12 September, outside the window, and I could not open a primary court filing.
- A JAMA piece on cardiovascular risk across nicotine products, dated 18 September. This is the one I most wanted. The journal’s site would not serve the article. If it holds up it is next week’s lead.
What to watch
- 2 October: the UK packaging, appearance and display consultation closes. The nicotine cap under the Tobacco and Vapes Act still arrives in regulations that do not yet exist.
- Fourth quarter: ZYN’s move to 20-count cans, and Altria’s stated plan to add flavours at 6, 9 and 12 mg — noting that 12 mg is not currently an authorised strength in the US.
- The FDA pilot programme. Authorisations arrived in January 2025, December 2025 and August 2026. Each one changes what may lawfully be sold.
- That JAMA paper.
This roundup is rebuilt every Sunday from the week’s tracker diff. Every claim above links to the document it came from; if a link does not say what I say it says, tell me and I will correct it.
Nicotine is addictive. No tobacco or nicotine product is safe, and completely stopping is the lowest-risk option. This site is for adults who already use nicotine — 21+ in the United States, 18+ or your local legal age elsewhere. Nothing here is medical advice.